Maurice R. G. O’Gorman

  • Citations Per Year
Learn More
KEITH A. REIMANN,* MAURICE R. G. O’GORMAN, JOHN SPRITZLER, CYNTHIA L. WILKENING, DANIEL E. SABATH, KAREN HELM, DONALD E. CAMPBELL, AND THE NIAID DAIDS NEW TECHNOLOGIES EVALUATION GROUP† Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts; Children’s Memorial(More)
Hepatoblastoma (HB) is the most common primary liver cancer in children. The conventional serum marker for HB, alpha-fetoprotein (AFP), has its limitations. Novel serum markers need to be explored. Glypican 3 (GPC3) has been reported to be an excellent histological immunomarker for HB. However, the clinical value of serum GPC3 in patients with HB is(More)
National AIDS Research Institute, Pune, India Kenya Medical Research Institute/US CDC Research and Public Health Collaboration, Kisumu, Kenya US Centers for Disease Control and Prevention (CDC-Kenya), Kisumu, Kenya Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand San Francisco General Hospital, San Francisco, CA, USA Children’s(More)
Major histocompatibility complex class II (MHCII) deficiency represents a rare form of severe immunodeficiency associated with increased susceptibility to viral, bacterial, and fungal pathogens and commonly leads to failure to thrive and early death. This autosomal recessive disorder is caused by mutations in MHCII transcription regulator genes, resulting(More)
  • 1